Advice
Results tables
Results tables
Table 6 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2015)
Bisphosphonates |
Control |
Analysis |
|
Total n=18,766 |
n=9,856 |
n=8,910 |
|
Primary outcomes |
|||
Rate of recurrence of breast cancer |
16.3% at 5 years 24.9% at 10 years |
17.4% at 5 years 25.9% at 10 years |
Difference at 10 years 1.1% (95% CI −0.7% to 2.9%), NSS Rate ratio 0.94 (95% CI 0.87 to 1.01) p=0.08, NSS |
Rate of distant recurrence |
13.5% at 5 years 20.4% at 10 years |
14.8% at 5 years 21.8% at 10 years |
Difference at 10 years 1.4% (95% CI −0.3% to 3.1%), NSS Rate ratio 0.92 (95% CI 0.85 to 0.99) p=0.03 |
Rate of breast cancer mortality |
8.9% at 5 years 16.6% at 10 years |
9.7% at 5 years 18.4% at 10 years |
Difference at 10 years 1.7% (95% CI 0.0% to 3.5%) Rate ratio 0.91 (95% CI 0.83 to 0.99) p=0.04 |
Selected secondary outcome |
|||
Bone recurrence |
4.7% at 5 years 7.8% at 10 years |
5.9% at 5 years 9.0% at 10 years |
Difference at 10 years 1.1% (95% CI −0.1% to 2.3%), NSS Rate ratio 0.83 (95% CI 0.73 to 0.94) p=0.004 |
All-cause mortality |
10.6% at 5 years 20.8% at 10 years |
11.4% at 5 years 22.3% at 10 years |
Difference at 10 years 1.6% (95% CI −0.36 to 3.56), NSS Rate ratio 0.92, 95% CI 0.85 to 1.00, p=0.06 |
Prespecified subgroup analyses in postmenopausal women |
|||
Total n=11,767 |
n=6,099 |
n=5,668 |
|
Rate of recurrence of breast cancer |
13.4% at 5 years 22.8% at 10 years |
15.8% at 5 years 25.8% at 10 years |
Difference at 10 years 3.0% (95% CI 0.5% to 5.5%) Rate ratio 0.86 (95% CI 0.78 to 0.94) p=0.002 |
Rate of distant recurrence |
11.1% at 5 years 17.9% at 10 years |
13.6% at 5 years 21.2% at 10 years |
Difference at 10 years 3.4% (95% CI 1.0% to 5.8%) Rate ratio 0.82 (95% CI 0.74 to 0.91) p=0.0003 |
Rate of breast cancer mortality |
7.5% at 5 years 14.7% at 10 years |
8.7% at 5 years 18.0% at 10 years |
Difference at 10 years 3.3% (95% CI 0.8% to 5.7%) Rate ratio 0.82 (95% CI 0.73 to 0.93) p=0.002 |
Bone recurrence |
3.6% at 5 years 6.6% at 10 years |
5.4% at 5 years 8.8% at 10 years |
Difference at 10 years 2.2% (95% CI 0.6% to 3.8%) Rate ratio 0.72 (95% CI 0.60 to 0.86) p=0.0002 |
All-cause mortality |
9.5% at 5 years 21.1% at 10 years |
10.8% at 5 years 23.5% at 10 years |
Difference at 10 years 2.3% (95% CI −0.64 to 5.24), NSS Rate ratio 0.86, 95% CI 0.77 to 0.96, p=0.005 |
Safety and tolerability outcomes |
|||
Although data on safety outcomes was collected, results are not reported in the paper. From the data obtained, it was not possible to assess the incidence of osteonecrosis of the jaw |
|||
Abbreviations: CI, confidence interval; NSS, not statistically significant; p, p value |